Table 4.

Data of clinical score and macroscopic evaluation of colitis in control and treatment groups after 7 days treatment

Groups	A	B	C *+	D *	E	F	G	H	I
ΔBW(g)	28.3 ± 1.6	-34 ± 5.0	11.5 ± 2.4*+	3.5 ± 2.7	4.2 ± 2.8	-20 ± 3.2	-5 ± 5.1	17.8 ± 1.7	9 ± 6.9
Cw /Bw (mg/g)	2.5 ± 0.7	12.9 ± 0.7	6.6 ± 0.9*+	9.1 ± 0.2	8.4 ± 0.2	10.7 ± 0.9	5.5 ± 0.3*	4.7 ± 0.4*	3.6 ± 0.6*
Ulcerative area (%)	0.0 ± 0.0	69.7 ± 5.3	28.6 ± 3.5*+	50.2 ± 4.1	51.8 ± 3.7	71.8 ± 3.9	40 ± 7.8*	24 ± 6.5*	13.1 ± 0.9*
Macroscopic score	0.0 ± 0.0	3.0 ± 0.0	2.4 ± 0.3	2.7 ± 0.2	2.7 ± 0.3	2.8 ± 0.4	2.7 ± 0.2	2.1 ± 0.4	2.0 ± 0.08

ΔBW = Body Weight change; Cw/Bw = Colon weight to body weight ratio; Ulcerative area (%) = Ulceration area /Total area of 8 cm colon; A = Normal group; B = Colitis group; C = Budesonide pectin-coated pellets (300 μg/Kg/day); D = Budesonide solution (300 μg/Kg/day); E = Budesonide uncoated pellets (300 μg/Kg/day); F = Placebo pellets; G = Mesalazine enema (400 mg/Kg/day, rectally); H = Budesonide enema (20 mcg/Kg/day, rectally); I = Prednisolone (5 mg/Kg/day, oral).

The results were expressed as mean ± SEM, (n = 6).*p < 0.05, denote significant difference vs. colitis control group; +p < 0.05 denote significant difference vs. budesonide solution, budesonide uncoated pellets.